BRIEF—Novo Nordisk launches Rebinyn eight months after US approval

Novo Nordisk has launched Rebinyn (coagulation factor IX recombinant) in the USA. The Danish firm’s extended half-life hemophilia B treatment was approved by the US FDA in June last year.

The treatment was approved on the basis of the Phase III paradigmTM trial, in which a single dose of Rebinyn elevated factor activity above baseline levels by 94%.

Adults also achieved an 83-hour average half-life after receiving a single infusion.

Corporate VP of biopharmaceuticals Pia D’ Urbano said: “The introduction of Rebinyn energizes us to build on our rich legacy of making innovative medicines available for people with rare bleeding disorders.”